Significance of Trained Immunity Involving HERV-K102 Activation in Promoting Recovery from COVID-19
An Investigative Report, June 27, 2022 v.2
UPDATE:
While the 105 page report with 204 references submitted on May 17, 2022 was regrettably rejected on June 22, 2022 due to the review article being outside the purview of the special volume on new paradigms in vaccination, SURPRISINGLY, a new email received June 27, 2022 has since asked for a vastly shortened revision (cutting the technical descriptions and certain sections) which would focus on the HERV-K102 protection mechanisms in trained immunity and in recovery from COVID-19. Moreover they are asking for visual representation of the protector mechanisms. For this purpose I had already devised these graphics (let me know if you think these are useful):
As such, I will take this potential opportunity to publish in a peer-reviewed journal, the proposal that innate immunity vaccines which activate the HERV-K102 protection system may be more suitable against (enveloped) pandemic RNA viruses than adaptive immunity vaccines.
I am still planning to make this highly technical investigative COVID-19 Report and all updates, available by subscription on this hervk102.substack.com blog with possible eventual publication as a book. I am looking forward to adding new information on the pathogenesis of Omicron and its variants as this information becomes available.
I am attaching the Executive Summary for this report for your immediate information and as a means to spark interest in the full report. The revised report should be available within a few weeks.
At first the recent reports of increased risk of cancer in the fully vaccinated were somewhat surprising to me given that the first dose of the mRNA vaccines produces about 60-70% heterologous protection against non-COVID-19 mortality which is largely unchanged by the administration of the second dose [Xu S et al., MMWR 2021, doi: http://dx.doi.org/10.15585/mmwr.mm7043e2]. However, this protection is effectively abrogated upon subsequent SARS-CoV-2 infection. We have seen that the omicron based variants are much more highly infectious meaning that in most fully vaccinated (2 doses or more) by now the heterologous protection against tumors has been extinguished related to infection with omicron variants. As well, the heterologous protection by trained immunity involving HERV-K102 is temporary, and may only last up to one year [Kaul R et al, J Clin Investigation, 2001]. Accordingly, for many of us vaccinated with two doses, it is now over 1 year since the second dose. Thus, if cancer rates for 2021 are compared with 2022 (especially in the vaccinated), one would expect to see an increase in 2022.
Marian, would you be willing to present your findings to Stephen Frost’s group?